354 related articles for article (PubMed ID: 26598745)
1. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Geyer H; Scherber R; Kosiorek H; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Maldonado N; Barosi G; Ferrari ML; Gale RP; Birgegard G; Xu Z; Zhang Y; Sun X; Xu J; Zhang P; te Boekhorst PA; Commandeur S; Schouten H; Pahl HL; Griesshammer M; Stegelmann F; Lehmann T; Senyak Z; Vannucchi AM; Passamonti F; Samuelsson J; Mesa RA
J Clin Oncol; 2016 Jan; 34(2):151-9. PubMed ID: 26598745
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
3. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
Grunwald MR; Burke JM; Kuter DJ; Gerds AT; Stein B; Walshauser MA; Parasuraman S; Colucci P; Paranagama D; Savona MR; Mesa R
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):579-584.e1. PubMed ID: 31303457
[TBL] [Abstract][Full Text] [Related]
4. Assessing disease burden in patients with classic MPNs.
Geyer H; Mesa RA
Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.
Chiaranairungrot K; Kaewpreechawat K; Sajai C; Pagowong N; Sukarat N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L; Rattarittamrong E
Hematology; 2022 Dec; 27(1):813-819. PubMed ID: 35894859
[TBL] [Abstract][Full Text] [Related]
6. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
[TBL] [Abstract][Full Text] [Related]
7. The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.
Scherber RM; Geyer HL; Dueck AC; Kosiorek HE; Finazzi G; Cavazzina R; Masciulli A; Scarano M; Vannucchi AM; Mesa RA; Barbui T
Leuk Lymphoma; 2017 Jun; 58(6):1481-1487. PubMed ID: 27830999
[TBL] [Abstract][Full Text] [Related]
8. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
9. Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.
Sonmez M; Saglam F; Karahan SC; Erkut N; Mentese A; Sonmez B; Ucar F; Topbas M; Ovali E
Hematology; 2010 Dec; 15(6):391-6. PubMed ID: 21114901
[TBL] [Abstract][Full Text] [Related]
10. Increased serum levels of vascular endothelial growth factor correlate with splenomegaly in polycythemia vera.
Murphy P; Ahmed N; Hassan HT
Leuk Res; 2002 Nov; 26(11):1007-1010. PubMed ID: 12363469
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.
Jentsch-Ullrich K; Eberhardt J; Zeremski V; Koehler M; Wolleschak D; Heidel FH
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2041-9. PubMed ID: 27431664
[TBL] [Abstract][Full Text] [Related]
13. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
15. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
17. [The relationship between symptom burden and hematologic responses after treatment with interferon/hydroxyurea in patients with polycythemia vera].
Liu D; Xu ZF; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):635-641. PubMed ID: 34547868
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
[TBL] [Abstract][Full Text] [Related]
19. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Nazha A; Khoury JD; Verstovsek S; Daver N
Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
[TBL] [Abstract][Full Text] [Related]
20. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
